Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.

Trial Details

NCT ID
NCT04025450
Phase
PHASE1 / PHASE2
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Chidamide+VRD
  • VRD
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Diagnosed as multiple myeloma, and has one of the above:
  • high risk karyotype, such as 17p-,t(4;14),t(14;16),t(14;20)或1q gain,1p-, double hit myeloma, triple hit myeloma, etc;
  • IgD/IgE MM;
  • with measurable extra-medullary plasmacytoma;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →